Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation
Nayyar, Moez, Menezes, Ricardo C. B. de , Parrondo, Ricardo , Nayyar, Madhavi , Parrondo, Ricardo D , Ailawadhi, Sikander

Cancers | July 10, 2025 | Volume: 17 | Issue: 14 | Pages: 2298

10.3390/cancers17142298 | PMID 40723181 Get It

CLL is the most prevalent adult leukemia in Western countries, characterized by the accumulation of monoclonal B lymphocytes. Over the past decade, the therapeutic landscape for CLL has undergone significant transformations, primarily due to the introduction of targeted small molecular therapies like BTK inhibitors and BCL-2 inhibitors, that have improved patient outcomes drastically. Despite significant advances, long-term disease management remains challenging for patients with double-refractory CLL, where responses with subsequent therapies are short-lived. Resistance to these therapies can arise through several mechanisms like kinase-altering BTK mutations, alterations in the BCL-2 pathway, and adaptations within the tumor microenvironment, necessitating the exploration of new therapeutic options. This review provides an in-depth overview of the promising novel treatment approaches under investigation in CLL, focusing on advanced cellular therapies (CAR T-cell therapy), T-cell engagers, new monoclonal antibodies, and various next-generation small molecule inhibitors including BTK degraders, PI3K inhibitors, MALT1 inhibitors, c-MYC inhibitors, CDK9 inhibitors, and agents targeting angiogenesis and DNA damage repair. In this review, we will discuss the novel therapeutic targets and agents as well as ongoing trials, emphasizing the potential of these treatments to overcome resistance and meet the unmet needs of patients, particularly those with double-refractory CLL.
Redefining risk stratification in pLCH
Abeykoon, Jithma P. , Tobin, W. Oliver , Tobin, W Oliver

Blood | July 10, 2025 | Volume: 146 | Issue: 2 | Pages: 136-138

10.1182/blood.2025029134 | PMID 40638205 Get It

Ophthalmic Knowledge Assessment Program Scores and Written Qualifying Examination Performance
Thanitcul, Chanon, Schnabel, Sarah , Bartley, George B., Lee, Andrew G., Crump, Hally, Fajardo, Dale , Peters, Kathryn F., Wilson, Beth, Peters, Kathryn, Srikumaran, Divya S.

JAMA Ophthalmology | July 10, 2025 | Volume: 143 | Issue: 8 | Pages: 678

10.1001/jamaophthalmol.2025.1933 | PMID 40638098 Get It

ImportanceThe Ophthalmic Knowledge Assessment Program (OKAP) has been widely used to determine readiness to take the high-stakes Written Qualifying Examination (WQE). However, it is unclear how well OKAP performance can predict WQE outcomes.ObjectiveTo examine the association between the OKAP and WQE nationally.Design, Setting, and ParticipantsThis was a retrospective cohort study conducted from 2017 to 2022. This national data analysis included residents from ophthalmology residency programs in the US. Study data were analyzed June 2023 to December 2024.ExposuresOKAP and WQE data.Main Outcomes and MeasuresThe national OKAP examination data and the WQE data were matched. Candidates who had complete data for the OKAP during postgraduate year (PGY) 2, 3, and 4 and completed the WQE were included in the study. Two-sample t tests, logistic regression analysis, receiver operating characteristic curves, and confusion matrix were used to examine the association of various test scores (PGY-2 OKAP, PGY-3 OKAP, PGY-4 OKAP, minimum OKAP, maximum OKAP, average OKAP) as predictors for WQE outcomes (pass or fail). Multiple logistic regression analyses were also used to assess the association of gender, time since graduation, program size, and WQE pass/fail outcomes.ResultsA total of 1597 residents (907 male [56.8%]) from 117 residency programs were included in this study. First-time pass rate of the WQE was 89% (1418 of 1597 residents). OKAP scores, particularly average OKAP, maximum OKAP, and PGY-4 OKAP scores (all had area under the curve = 0.88), were the most useful predictor of WQE outcomes. PGY-4 OKAP scores were used for the rest of the analysis for simplicity. A PGY-4 OKAP scaled score of 550 corresponded to 94% of candidates passing the WQE. Using PGY-4 OKAP scores to predict passing/failing, the WQE had 90.7% accuracy. Gender (odds ratio [OR], 1.50; 95% CI, 1.01-2.26; P = .048), program size (OR, 1.55; 95% CI, 0.98-2.41; P = .06), and time since residency graduation (OR, 1.00; 95% CI, 1.00-1.00; P = .14) were not included in the logistic regression model investigating the association of PGY-4 OKAP scores with the likelihood of passing the WQE.Conclusions and RelevanceResults suggest that OKAP examination scores were associated with passing the WQE after adjusting for program size, gender, and time since residency graduation. Further analyses may be warranted to predict failing the WQE so that potential interventions can be attempted.
Minimal Clinically Important Difference and Relative Change in Patient-Reported Outcomes After Surgery for Cervical Spondylotic Myelopathy: A Nationwide Study of 1,700 Patients
El-Hajj, Victor Gabriel , Staartjes, Victor E. , Atallah, Elias , Babaei, Darius, Bydon, Mohamad , Elmi‐Terander, Adrian , Elmi-Terander, Adrian , El-Hajj, Victor Gabriel , Staartjes, Victor E , Klukowska, Anita Maria , Gerdhem, Paul , Edström, Erik

Neurosurgery | July 10, 2025 | Volume: 98 | Issue: 2 | Pages: 358-364

10.1227/neu.0000000000003596 | PMID 40637438 Get It

BACKGROUND AND OBJECTIVES: Healthcare policies have seen significant reforms, with a marked transition toward a patient-centered approach. This shift emphasizes the use of subjective patient-reported outcome measures as key metrics. However, these measures often face limitations, particularly in identifying clinically meaningful changes over time. To address this challenge, the concept of the minimal clinically important difference (MCID) was introduced. This study aims to evaluate the predictive effectiveness of relative change and its associated threshold, the minimal clinically important relative change (MCIRC), as a potential alternative to absolute differences and the MCID. METHODS: Data prospectively collected between 2006 and 2021 from the Swedish Spine Registry (Swespine) were analyzed. Patient-reported outcome measures included the Numeric Rating Scale (NRS) for neck and arm pain, the EQ5D index, EQ VAS, and the Neck Disability Index (NDI). Anchor-based methods were used to calculate the MCID and MCIRC. The predictive performance of absolute differences and relative changes was compared using the area under the receiver operating characteristic curve. RESULTS: 1756 patients were included. The selected MCID values were −3 for NRS neck pain intensity, −2 for arm pain intensity, 0.09 for the EQ5D index, 7 for EQ VAS, and −12 for NDI scores. For MCIRC, the chosen values were −47% for NRS neck pain intensity, −40% for arm pain intensity, 386% for the EQ5D index, 52% for EQ VAS, and −32% for NDI scores. On area under the ROC curve, relative change was superior for NRS neck and arm pain scores and NDI, while absolute difference was superior for EQ5D and EQ VAS scores. CONCLUSION: Relative change, along with its associated minimal clinically important value (MCIRC), proved to be a more suitable indicator of subjective satisfaction for NRS and NDI scores. By contrast, absolute differences and the MCID were better suited for evaluating the EQ5D index and EQ VAS scores.
Perioperative Transfusion Following Total Laryngectomy: A Nationwide Study
Jategaonkar, Gaurav A. , Hintze, Justin M. , Chang, Brent A. , Jategaonkar, Ameya A. , Chang, Brent A , Hintze, Justin , Xie, Deborah X.

The Laryngoscope | July 10, 2025 | Volume: 135 | Issue: 12 | Pages: 4732-4741

10.1002/lary.32392 | PMID 40637378 Get It

ABSTRACT Objective Total laryngectomy (TL) represents a major operation often performed on medically complex patients. The impact of blood transfusion in TL patients is not well defined. Here, we utilize a national database to characterize these patients and further investigate a potential dose‐dependent relationship between transfusion and postoperative outcomes. Methods The National Surgical Quality Program (NSQIP) was queried for patients who underwent TL with/without neck dissection (CPT 31360, 31365) between 2014 and 2022. Total units of transfused blood were only available for patients between 2020 and 2023. Statistical analysis involved hypothesis testing, multivariate logistic regression, and receiver operating characteristic (ROC) analysis. Results Among 2311 patients, 413 (17.9%) received transfusions. Non‐White race, ASA Class ≥ 3, hypertension, cancer with distant metastases, bleeding disorders, and elevated BUN, WBC, and INR were associated with transfusion ( p < 0.05). Multivariate analysis identified hypertension (OR 1.81), bleeding disorders (OR 2.64), ASA ≥ 3 (OR 2.40), concurrent free flap (OR 3.75) and lower hematocrit (OR 0.85) as predictors. Transfused patients had longer hospital stays (12 vs. 9 days), increased complications (e.g., stroke, DVT), higher reoperation (23.2% vs. 13.9%) and mortality (2.7% vs. 0.8%) ( p < 0.05). ROC analysis suggested transfusion > 2.5 units was associated with adverse outcomes. Conclusion TL remains a major surgical endeavor that can be associated with lengthy and complicated hospital courses. We show that perioperative transfusion may be associated with increased hospital stay, reoperation, and mortality in TL patients, with a potential dose‐dependent effect. Our study reinforces the risks associated with blood transfusion and further supports the thoughtful utilization of blood products in TL patients. Level of Evidence 3.
NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025
Haddad, Robert I. , Bischoff, Lindsay , Applewhite, Megan K. , Bernet, Victor , Blomain, Erik , Brito, Maria , Busaidy, Naifa L. , Campbell, Michael J. , DeLozier, Olivia M. , Duh, Quan‐Yang , Ehya, Hormoz, Grady, Erin C., Hunt, Jason P. , Kandeel, Fouad , Lamonica, Dominick , Lorch, Jochen H. , Mandel, Susan J., Mydlarz, Wojciech K. , Raeburn, Christopher D., Rezaee, Rod , Ritter, Hadley E., Roth, Mara Y. , Salgado, Sarimar Agosto , Scheri, Randall P., Sipos, Jennifer A. , Wirth, Lori J. , Darlow, Susan, Cassara, Carly J., Sliker, Bailee , Haddad, Robert , Guo, Theresa , Haymart, Megan R. , Kotwal, Anupam , Markovina, Stephanie T. , Nabell, Lisle M. , Ridge, John Andrew , Shah, Jatin P. , Sippel, Rebecca S. , Sturgeon, Cord , Wong, Richard J. , Worden, Francis P. , Yeh, Michael W.

Journal of the National Comprehensive Cancer Network | July 10, 2025 | Volume: 23 | Issue: 7 | Pages: No page available

10.6004/jnccn.2025.0033 | PMID 40639400 Get It

The NCCN Guidelines for Thyroid Carcinoma address the management of different types of thyroid carcinoma, including papillary, follicular, oncocytic, medullary, and anaplastic carcinoma. The NCCN Thyroid Carcinoma Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights focus on the panel’s most recent recommendations regarding systemic therapies for thyroid carcinoma as well as the supporting clinical data.
Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Swarm, Robert A., Youngwerth, Jeanie, Anițescu, Magdalena , Are, Madhuri , Buga, Sorin , Butler, Taylor, Cleary, James F. , Copenhaver, David, Coyne, Christopher , Craig, David S., Finnes, Heidi D. , Greenlee, Heather , Gupta, Mona, Hansen, Eric, Javed, Saba , Kandil, Enas , Mackey, Sean , McGrath, Kathryn, Moryl, Natalie , Nesbit, Suzanne , Noonan, Michael , Norris, Joseph, Pršić, Elizabeth , Rabow, Michael W. , Rickerson, Elizabeth , Sindt, Jill E. , Vorenkamp, Kevin E. , Cunningham, Rebecca, Gurski, Lisa A., Jones, Frankie, Finnes, Heidi, Agne, Julia L. , Butler, Taylor, Chwistek, Marcin , Gupta, Mona, Javed, Saba , McDonald, Andrew, Noonan, Michael, Paice, Judith A. , SMITH, MICHAEL D. , Bruce, Justine Y. , Yoo, Sun

Journal of the National Comprehensive Cancer Network | July 10, 2025 | Volume: 23 | Issue: 7 | Pages: No page available

10.6004/jnccn.2025.0032 | PMID 40639401 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Adult Cancer Pain provide recommendations for the comprehensive management of pain in patients with cancer. This article will focus on methods for screening for pain, safe and appropriate prescription of opioid and miscellaneous analgesics, and the optimization of nonpharmacologic interventions including integrative and interventional strategies for treatment of cancer-related pain. Additionally, the NCCN Guidelines discuss methods for the safe reduction of opioids when appropriate, as well as techniques for encouraging the judicious use of opioids. The complete version of the NCCN Guidelines for Adult Cancer Pain addresses additional issues that are not covered here, including management of pain during a pain crisis, management of procedure-related pain and anxiety, pain management for cancer survivors, and the use of nonopioid and adjuvant analgesics for cancer-related pain.
Post-infarct effusive-constrictive pericarditis with a percutaneous left ventricular assist device: a case report
Kan, Jonah , Asleson, Louise , Inestroza, Karla , Jentzer, Jacob C. , Hillerson, Dustin , Jentzer, Jacob C , Inestroza, Karla , Hillerson, Dustin

European Heart Journal - Case Reports | July 10, 2025 | Volume: 9 | Issue: 7 | Pages: No page available

10.1093/ehjcr/ytaf326 | PMID 40718654 Get It

Abstract Background Effusive-constrictive pericarditis (ECP) is a condition where acute pericarditis causes a pericardial effusion and stiffening of the pericardium, which can result in haemodynamic instability due to compression of right-sided cardiac chambers. Here, we present a patient with cardiac tamponade followed by ECP complicating treatment of acute myocardial infarction/cardiogenic shock supported with a percutaneous left ventricular assist device (PVAD). Case summary A 65-year-old male presented with an anterior ST-elevation myocardial infarction and cardiogenic shock. The left anterior descending artery was stented, and a PVAD was placed. The patient was haemodynamically unstable, and the PVAD had frequent suction alarms at higher flow rates. Pulsus paradoxus was noted on the arterial line tracing. Echocardiography showed a large pericardial effusion, which was drained with improvement in cardiac output. However, the patient soon worsened again with continued PVAD suction alarms, and this time echocardiography demonstrated constrictive physiology. The patient was treated with anti-inflammatory medications with improvement in haemodynamics. The PVAD was able to be weaned, and the patient was discharged in stable condition. Discussion Effusive-constrictive pericarditis is a syndrome exhibiting the physiology of both cardiac tamponade and constrictive pericarditis. Effusive-constrictive pericarditis should be considered in patients whose haemodynamics do not improve after pericardiocentesis. This patient had a PVAD placed, which relies on left ventricular preload to increase cardiac output. The numerous suction alarms encountered during this patient’s intensive care unit course were likely due to ECP decreasing preload.
Plasma Metabolomics, Lipidomics, and Acylcarnitines Are Associated With Vision and Genotype but Not With Dietary Intake in Long‐Chain 3‐Hydroxyacyl‐ CoA Dehydrogenase Deficiency (
Chung, H. , Gregor, Ashley, Sim, Elaine, Lau, Alison, Black, Danielle, Scanga, Hannah L. , Linshinski, Angela, Yang, Paul , Matern, Dietrich , Gillingham, Melanie B , Chung, Hak, Choi, Dongseok , Lau, Alison, Black, Danielle, Pennesi, Mark Edward , Sahel, José‐Alain , Nischal, Ken Kanwal , Everett, Lesley A , Vockley, Jerry , Harding, Cary O. , Gillingham, Melanie B.

Journal of Inherited Metabolic Disease | July 10, 2025 | Volume: 48 | Issue: 4 | Pages: No page available

10.1002/jimd.70060 | PMID 40635623 Get It

ABSTRACT 3‐hydroxy acylcarnitines (3‐OH‐ACs) are key biomarkers for screening of long‐chain 3‐hydroxyacyl‐CoA dehydrogenase and trifunctional protein deficiencies (LCHADD/TFPD). The utility of this biomarker for disease monitoring in identified patients remains debated, and recent suggestions have highlighted the potential use of lipidomics for diagnosis, monitoring, prognosis, and/or identification of new biomarkers. We evaluated the use of omics in LCHADD/TFPD patients by analyzing plasma acylcarnitine profiles, metabolomics, and lipidomics, combined with genotype, visual assessments, and dietary records. Fasting plasma from 39 participants with LCHADD/TFPD and 32 control subjects were analyzed through untargeted metabolomic and lipidomic analyses. In LCHADD/TFPD participants, acylcarnitine profiling, visual and retinal function assessments were performed, and 3‐day diet records were collected. Relationships between acylcarnitines, metabolomics, lipidomics, along with visual outcomes and dietary intake were investigated. Plasma of LCHADD/TFPD participants exhibited elevated 3‐OH‐ACs, which correlated with genotype and visual outcomes. Metabolomics successfully distinguished LCHADD/TFPD from controls, and the biggest divergence was observed in lipid pathways. Metabolomic profiles tightly correlated with 3‐OH‐ACs, genotype, and visual outcomes. Lower concentrations of total lipids and some individual lipid species such as phosphoethanolamines (PE) were detected in LCHADD/TFPD, except for elevations in several certain triglycerides. LCHADD/TFPD participants followed a diet low in long‐chain fat (LCFA) as recommended. LCFA intake did not correlate with either plasma 3‐OH‐ACs or metabolomics. 3‐OH‐ACs are strong consistent biomarkers of LCHADD/TFPD that are associated with clinical parameters of vision and genotype. We did not observe a relationship between dietary LCFA intake and 3‐OH‐ACs.
Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review
Lee, Taeweon , Gianchandani, Ayushi, Boorjian, Stephen A. , Narayan, Vikram M. , Narayan, Vikram M , Shore, Neal D. , Dinney, Colin P. , Kamat, Ashish M.

Future Oncology | July 10, 2025 | Volume: 21 | Issue: 19 | Pages: 2429-2438

10.1080/14796694.2025.2527593 | PMID 40635630 Get It